Acrux, an Australian company has recently announced that it’s roll-on testosterone delivery system (think underarm deodorant)  been picked up by Eli Lilly in a deal worth more than $335m dollars (before royalties).

If the United States F.D.A. approves the mediation, Eli Lilly will have the right to market the product to 143 countries.

In the past, transdermal testosterone preparations have been eschewed by the black market for reasons including cost, availability, and most commonly performance versus injectable versions.